Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026
Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026
Company Deals Drug

Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China

Fineline Cube Sep 27, 2022

Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...

Company

Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute

Fineline Cube Sep 27, 2022

Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...

Company Deals

Hansoh Pharmaceutical Licenses KiOmedine One for Osteoarthritis Treatment

Fineline Cube Sep 27, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with Belgium’s...

Company Deals

Ubrigene Raises Hundreds of Millions in Series C Financing Round

Fineline Cube Sep 27, 2022

Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...

Company Medical Device

China’s First Proton Therapy System Approved by NMPA

Fineline Cube Sep 27, 2022

The National Medical Products Administration (NMPA) has approved the proton therapy system developed by Shanghai...

Company Drug

Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296

Fineline Cube Sep 27, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...

Company Drug

Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19

Fineline Cube Sep 27, 2022

China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....

Company

China Resources Pharma Reports Strong Interim Results Amid COVID-19

Fineline Cube Sep 27, 2022

China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report,...

Company Deals

Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development

Fineline Cube Sep 27, 2022

Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...

Company Drug

Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema

Fineline Cube Sep 26, 2022

China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...

Company Deals

Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs

Fineline Cube Sep 26, 2022

China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano...

Company Deals

ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation

Fineline Cube Sep 26, 2022

ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has...

Company Drug

Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171

Fineline Cube Sep 26, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...

Company Drug

Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study

Fineline Cube Sep 26, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...

Company Medical Device

Boston Scientific Completes First Surgery with RotaPro in China

Fineline Cube Sep 26, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using...

Company

Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns

Fineline Cube Sep 26, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...

Company Deals

Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal

Fineline Cube Sep 26, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...

Company Drug Legal / IP

HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya

Fineline Cube Sep 23, 2022

China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...

Company Deals

Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293

Fineline Cube Sep 23, 2022

Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...

Company

Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China

Fineline Cube Sep 23, 2022

The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...

Posts pagination

1 … 562 563 564 … 607

Recent updates

  • Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
  • FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
  • Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.